Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society

Tool Details

  • Tool name: MCF7/TAMR-8 Cell Line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF7 S0.5
  • Organism: Human
  • Tissue: Breast
  • Cancer type: Breast cancer, tamoxifen-resistant
  • Disease: Cancer
  • Conditional: Yes
  • Description: The MCF7/TAMR-8 Cell line is a breast cancer cell line resistant to tamoxifen. Tamoxifen is by far the most widely used drug for hormone-dependent breast cancer. However, primary or acquired resistance to Tamoxifen severely limits its clinical effectiveness. The MCF7/TAMR-8 cell line is a good model cell to study the signalling pathways, which are the major drivers of tamoxifen-resistant growth. The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment with tamoxifen was started in passage 351. Few colonies of cells survived the treatment and after 28 days of tamoxifen treatment, tamoxifen was omitted from the medium for 22 days. After 19 passages without tamoxifen (passage 372) the cells underwent a second treatment with tamoxifen which initially reduced cell growth rate, but around 390-400 the growth rate of the tamoxifen resistant cell lines was close to the growth rate of the parental MCF7/S0.5 cells.
  • Research area: Cancer ; Drug Discovery & Development

  • For Research Use Only

Target Details

Application Details


  • Format: Frozen
  • Passage number: Passage 398 (AL2687, AL2688)
  • Growth medium: 37°C under 5% CO2 in air using phenol red-free DMEM:Ham's F-12 containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 ?M).
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1


  • Available on request


  •   Thrane et al. 2015. Oncogene. 34(32):4199-210. PMID: 25362855.
  •   Elias et al. 2015. Oncogene. 34(15):1919-27. PMID: 24882577.
  •   Pedersen et al. 2014. Int J Oncol. 45(5):2167-75. PMID: 25175082.
  •   A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
  •   Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor a.
  •   Lundqvist et al. 2014. Steroids. 85:30-5. PMID: 24747771.
  •   Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
  •   1a,25-dihydroxyvitamin D3 inhibits cell growth and NFB signaling in tamoxifen-resistant breast cancer cells.
  •   Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
  •   Estrogen receptor a is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.
  •   Larsen et al. 2012. Int J Oncol. 41(5):1863-70. PMID: 22961366.
  •   Cutrupi et al. 2012. Oncogene. 31(40):4353-61. PMID: 22249258.
  •   Carboplatin treatment of antiestrogen-resistant breast cancer cells.
  •   Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
  •   Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-79. PMID: 17061041.
  •   Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
  •   Beliakoff et al. 2003. Clin Cancer Res. 9(13):4961-71. PMID: 14581371.
  •   Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
  •   Madsen et al. 1995. Mol Cell Endocrinol. 109(2):197-207. PMID: 7664983.
  •   Differential expression of estrogen receptor mRNA splice variants in the tamoxifen resistant human breast cancer cell line, MCF-7/TAMR-1 compared to the parental MCF-7 cell line.